These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 38466213

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Upadacitinib (Rinvoq): A second JAK inhibitor for ulcerative colitis.
    Med Lett Drugs Ther; 2022 Sep 05; 64(1658):142-144. PubMed ID: 36094554
    [No Abstract] [Full Text] [Related]

  • 3. Etrasimod (Velsipity) for ulcerative colitis.
    Med Lett Drugs Ther; 2023 Nov 27; 65(1690):187-189. PubMed ID: 37983118
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risankizumab (Skyrizi) - An IL-23 antagonist for Crohn's disease.
    Med Lett Drugs Ther; 2022 Dec 26; 64(1666):153-157. PubMed ID: 36542348
    [No Abstract] [Full Text] [Related]

  • 8. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul 02; 60(1550):107-114. PubMed ID: 30036352
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bimekizumab (Bimzelx) for psoriasis.
    Med Lett Drugs Ther; 2024 Jan 22; 66(1694):11-13. PubMed ID: 38212257
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A, Modesto I, Sharma PP.
    J Med Econ; 2021 Jan 22; 24(1):279-290. PubMed ID: 33502905
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H.
    Expert Rev Gastroenterol Hepatol; 2021 Jun 22; 15(6):711-722. PubMed ID: 33599181
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Risankizumab (Skyrizi) for psoriasis.
    Med Lett Drugs Ther; 2019 Jun 03; 61(1573):81-83. PubMed ID: 31170118
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y, Paramsothy S, Yau Y, Leong RW.
    Aliment Pharmacol Ther; 2021 Aug 03; 54(3):292-301. PubMed ID: 34151447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.